LymphedemaV1, Ncbi, Merge, bibRecord, 004F58

Surgical treatment of melanoma patients with early sentinel node involvement.

Identifieur interne : 004F58 ( Ncbi/Merge ); précédent : 004F57; suivant : 004F59

Surgical treatment of melanoma patients with early sentinel node involvement.

Auteurs : Rosemarie E. Hardin [États-Unis] ; Julie R. Lange

Source :

Current treatment options in oncology [ 1534-6277 ] ; 2012.

RBID : pubmed:22810837

Descripteurs français

KwdFr :
- Biopsie de noeud lymphatique sentinelle, Charge tumorale, Essais cliniques comme sujet, Humains, Mélanome (), Mélanome (anatomopathologie), Métastase lymphatique, Noeuds lymphatiques (anatomopathologie).
MESH :
- anatomopathologie : Mélanome, Noeuds lymphatiques.
- Biopsie de noeud lymphatique sentinelle, Charge tumorale, Essais cliniques comme sujet, Humains, Mélanome, Métastase lymphatique.

English descriptors

KwdEn :
- Clinical Trials as Topic, Humans, Lymph Nodes (pathology), Lymphatic Metastasis, Melanoma (pathology), Melanoma (surgery), Sentinel Lymph Node Biopsy, Tumor Burden.
MESH :
- pathology : Lymph Nodes, Melanoma.
- surgery : Melanoma.
- Clinical Trials as Topic, Humans, Lymphatic Metastasis, Sentinel Lymph Node Biopsy, Tumor Burden.

Abstract

Sentinel lymph node biopsy (SLNB) is a standard staging procedure for many patients with clinically node negative, invasive melanoma, providing excellent prognostic information in appropriately selected patients. The broad acceptance of SLNB into clinical practice has resulted in substantial numbers of patients found to have microscopic nodal metastases. For patients with a positive sentinel node, a completion lymph node dissection (CLND) is the current standard of care. The majority of patients who undergo CLND are found to have histologically negative non-sentinel nodes, and yet are exposed to the potential morbidity of CLND, including infection, wound complications, and lymphedema. We do not yet know if there is a survival benefit from CLND that justifies its morbidity and we are currently unable to identify clinical and pathologic factors that may be associated with the likelihood of benefit from CLND. Controversy regarding the management of melanoma patients with a positive sentinel node highlights the need for continued investigation in melanoma biology, treatment, and outcomes. Patients with minimal tumor burden in their regional nodes would especially benefit from a better understanding of the appropriate management strategies. Ongoing clinical trials are aimed at determining whether CLND is superior to nodal observation and surveillance in patients with positive sentinel nodes, and at determining the outcome of patients with minimal disease in their sentinel node who forego CLND. These studies may help to resolve the uncertainties of the management in these patients. Until we have further information, CLND for melanoma patients with positive sentinel nodes remains the preferred, standard management strategy.

DOI: 10.1007/s11864-012-0202-8
PubMed: 22810837

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002033
to stream PubMed, to step Curation: 002033
to stream PubMed, to step Checkpoint: 002033

Links to Exploration step

pubmed:22810837

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Surgical treatment of melanoma patients with early sentinel node involvement.</title>
<author><name sortKey="Hardin, Rosemarie E" sort="Hardin, Rosemarie E" uniqKey="Hardin R" first="Rosemarie E" last="Hardin">Rosemarie E. Hardin</name>
<affiliation wicri:level="2"><nlm:affiliation>Johns Hopkins Medicine, Baltimore, MD 21287, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Johns Hopkins Medicine, Baltimore, MD 21287</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lange, Julie R" sort="Lange, Julie R" uniqKey="Lange J" first="Julie R" last="Lange">Julie R. Lange</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22810837</idno>
<idno type="pmid">22810837</idno>
<idno type="doi">10.1007/s11864-012-0202-8</idno>
<idno type="wicri:Area/PubMed/Corpus">002033</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002033</idno>
<idno type="wicri:Area/PubMed/Curation">002033</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002033</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002033</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002033</idno>
<idno type="wicri:Area/Ncbi/Merge">004F58</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Surgical treatment of melanoma patients with early sentinel node involvement.</title>
<author><name sortKey="Hardin, Rosemarie E" sort="Hardin, Rosemarie E" uniqKey="Hardin R" first="Rosemarie E" last="Hardin">Rosemarie E. Hardin</name>
<affiliation wicri:level="2"><nlm:affiliation>Johns Hopkins Medicine, Baltimore, MD 21287, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Johns Hopkins Medicine, Baltimore, MD 21287</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lange, Julie R" sort="Lange, Julie R" uniqKey="Lange J" first="Julie R" last="Lange">Julie R. Lange</name>
</author>
</analytic>
<series><title level="j">Current treatment options in oncology</title>
<idno type="eISSN">1534-6277</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Humans</term>
<term>Lymph Nodes (pathology)</term>
<term>Lymphatic Metastasis</term>
<term>Melanoma (pathology)</term>
<term>Melanoma (surgery)</term>
<term>Sentinel Lymph Node Biopsy</term>
<term>Tumor Burden</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Biopsie de noeud lymphatique sentinelle</term>
<term>Charge tumorale</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Mélanome ()</term>
<term>Mélanome (anatomopathologie)</term>
<term>Métastase lymphatique</term>
<term>Noeuds lymphatiques (anatomopathologie)</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Mélanome</term>
<term>Noeuds lymphatiques</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lymph Nodes</term>
<term>Melanoma</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Melanoma</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Humans</term>
<term>Lymphatic Metastasis</term>
<term>Sentinel Lymph Node Biopsy</term>
<term>Tumor Burden</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Biopsie de noeud lymphatique sentinelle</term>
<term>Charge tumorale</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Mélanome</term>
<term>Métastase lymphatique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Sentinel lymph node biopsy (SLNB) is a standard staging procedure for many patients with clinically node negative, invasive melanoma, providing excellent prognostic information in appropriately selected patients. The broad acceptance of SLNB into clinical practice has resulted in substantial numbers of patients found to have microscopic nodal metastases. For patients with a positive sentinel node, a completion lymph node dissection (CLND) is the current standard of care. The majority of patients who undergo CLND are found to have histologically negative non-sentinel nodes, and yet are exposed to the potential morbidity of CLND, including infection, wound complications, and lymphedema. We do not yet know if there is a survival benefit from CLND that justifies its morbidity and we are currently unable to identify clinical and pathologic factors that may be associated with the likelihood of benefit from CLND. Controversy regarding the management of melanoma patients with a positive sentinel node highlights the need for continued investigation in melanoma biology, treatment, and outcomes. Patients with minimal tumor burden in their regional nodes would especially benefit from a better understanding of the appropriate management strategies. Ongoing clinical trials are aimed at determining whether CLND is superior to nodal observation and surveillance in patients with positive sentinel nodes, and at determining the outcome of patients with minimal disease in their sentinel node who forego CLND. These studies may help to resolve the uncertainties of the management in these patients. Until we have further information, CLND for melanoma patients with positive sentinel nodes remains the preferred, standard management strategy.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22810837</PMID>
<DateCreated><Year>2012</Year>
<Month>08</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted><Year>2012</Year>
<Month>12</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2012</Year>
<Month>08</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1534-6277</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>13</Volume>
<Issue>3</Issue>
<PubDate><Year>2012</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Current treatment options in oncology</Title>
<ISOAbbreviation>Curr Treat Options Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>Surgical treatment of melanoma patients with early sentinel node involvement.</ArticleTitle>
<Pagination><MedlinePgn>318-26</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s11864-012-0202-8</ELocationID>
<Abstract><AbstractText>Sentinel lymph node biopsy (SLNB) is a standard staging procedure for many patients with clinically node negative, invasive melanoma, providing excellent prognostic information in appropriately selected patients. The broad acceptance of SLNB into clinical practice has resulted in substantial numbers of patients found to have microscopic nodal metastases. For patients with a positive sentinel node, a completion lymph node dissection (CLND) is the current standard of care. The majority of patients who undergo CLND are found to have histologically negative non-sentinel nodes, and yet are exposed to the potential morbidity of CLND, including infection, wound complications, and lymphedema. We do not yet know if there is a survival benefit from CLND that justifies its morbidity and we are currently unable to identify clinical and pathologic factors that may be associated with the likelihood of benefit from CLND. Controversy regarding the management of melanoma patients with a positive sentinel node highlights the need for continued investigation in melanoma biology, treatment, and outcomes. Patients with minimal tumor burden in their regional nodes would especially benefit from a better understanding of the appropriate management strategies. Ongoing clinical trials are aimed at determining whether CLND is superior to nodal observation and surveillance in patients with positive sentinel nodes, and at determining the outcome of patients with minimal disease in their sentinel node who forego CLND. These studies may help to resolve the uncertainties of the management in these patients. Until we have further information, CLND for melanoma patients with positive sentinel nodes remains the preferred, standard management strategy.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hardin</LastName>
<ForeName>Rosemarie E</ForeName>
<Initials>RE</Initials>
<AffiliationInfo><Affiliation>Johns Hopkins Medicine, Baltimore, MD 21287, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lange</LastName>
<ForeName>Julie R</ForeName>
<Initials>JR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Curr Treat Options Oncol</MedlineTA>
<NlmUniqueID>100900946</NlmUniqueID>
<ISSNLinking>1534-6277</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D021701" MajorTopicYN="N">Sentinel Lymph Node Biopsy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>7</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>7</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2012</Year>
<Month>12</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">22810837</ArticleId>
<ArticleId IdType="doi">10.1007/s11864-012-0202-8</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><noCountry><name sortKey="Lange, Julie R" sort="Lange, Julie R" uniqKey="Lange J" first="Julie R" last="Lange">Julie R. Lange</name>
</noCountry>
<country name="États-Unis"><region name="Maryland"><name sortKey="Hardin, Rosemarie E" sort="Hardin, Rosemarie E" uniqKey="Hardin R" first="Rosemarie E" last="Hardin">Rosemarie E. Hardin</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004F58 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004F58 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:22810837
   |texte=   Surgical treatment of melanoma patients with early sentinel node involvement.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:22810837" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Surgical treatment of melanoma patients with early sentinel node involvement.

Surgical treatment of melanoma patients with early sentinel node involvement.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki